McKesson Corp (MCK)

McKesson’s results in the third quarter reflected continued momentum in its core pharmaceutical distribution and specialty services. Management highlighted s...

Specialty growth and new deals lift the first-half outlook.

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...

Healthcare distributor and services company McKesson (NYSE:MCK) beat Wall Street’s revenue expectations in calendar Q3 2026 (fiscal Q2 2027), with revenue up...

Healthcare distributor and services company McKesson (NYSE:MCK) will be reporting earnings this Wednesday after market close. Here’s what investors should kn...

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not...

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are...

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...

The provider of home and alternate site infusion services is being acquired.

The company extended its existing partnership with a major pharmacy chain.

What Happened? Shares of healthcare distributor and services company McKesson (NYSE:MCK) jumped 4.4% in the afternoon session after the company reached an ag...

Since March 2026, McKesson has been in a holding pattern, floating around $872.99. The stock also fell short of the S&P 500’s 16.4% gain during that period. ...

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...

McKesson (NYSE:MCK) executives said the company’s first-quarter performance supported a higher full-year earnings outlook, citing broad-based growth across its North American Pharmaceutical, Oncology & Multispecialty and Prescription Technology Solutions businesses. Speaking at the Morgan Stanl

McKesson (NYSE:MCK) discussed its planned $2.25 billion acquisition of Precision Medicine Group, first-quarter operating trends and capital-allocation priorities during a presentation with Wells Fargo analyst Stephen Baxter. The company said Precision Medicine Group would expand two areas it has id

The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta y...

McKesson (NYSE:MCK) has outperformed the market over the past 10 years by 3.54% on an annualized basis producing an average annual return of 17.04%. Currently, McKesson has a market capitalization of $103.82 billion.

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

These healthcare companies can actually benefit from inflation.

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how healthcare providers &...

Cardinal Health stock hit a new all-time high after mixed earnings, with analyst price target hikes, gene therapy logistics wins and a 29-year dividend growth streak supporting the uptrend.

McKesson (NYSE:MCK) reported fiscal first-quarter 2027 results that exceeded its expectations, citing broad-based momentum across its operating businesses and prompting the healthcare services company to raise its full-year adjusted earnings outlook. Revenue rose 8% to $105.4 billion, while adjuste